The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

En bloc resection of bladder tumor has recently emerged as an alternative to TURBT aiming to improve surgical quality and pathological assessment.

Key market opportunities include growing demand for advanced, targeted bladder therapies, increased R&D in personalized & ...

A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with ...

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in ...

A 49-year-old unsigned commentary in The Lancet that's been used in litigation to prop up the safety of talc products has ...

The campaign for better prostate cancer awareness has provoked important questions about the lack of testing and screening. Why are men dying unnecessarily?

At a General Meeting on 11 June 2025, shareholders approved the subdivision and redesignation of the Company’s Issued ...

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...

For Grant Nerren, 2025 was a busy year, full of highs and lows that likely contributed to a certain level of stress. Life was ...

In this article, we will discuss the 9 Best Psychedelic Stocks to Buy in 2026. The AdvisorShares Psychedelics ETF, a fund ...